BS_0XEG6SNV
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- overall_survival_months
- 56.760000000000005
- os_event
- false
- age_years
- 11.548
- sex
- F
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.435870359
- umap2_2d
- 0.227028599
- umap1_3d
- 0.990147351
- umap2_3d
- 3.10434241
- umap3_3d
- -1.759758847
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.300
- ANGIOGENESIS+0.290
- MYOGENESIS+0.270
- TNFA_SIGNALING_VIA_NFKB+0.270
- APICAL_SURFACE+0.260
- INFLAMMATORY_RESPONSE+0.250
- APICAL_JUNCTION+0.170
- INTERFERON_ALPHA_RESPONSE+0.170
- INTERFERON_GAMMA_RESPONSE+0.160
- ALLOGRAFT_REJECTION+0.150
Top 10 suppressed
- MYC_TARGETS_V1-0.690
- OXIDATIVE_PHOSPHORYLATION-0.660
- PROTEIN_SECRETION-0.580
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.510
- MTORC1_SIGNALING-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.460
- MYC_TARGETS_V2-0.440
- DNA_REPAIR-0.420
- ADIPOGENESIS-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.938 |
| 2 | BS_GTZCFGRZ | Ganglioglioma | — | 0.927 |
| 3 | TCGA-97-A4M7-01A-11R-A24X-07 | — | cohortA1 | 0.921 |
| 4 | TCGA-CF-A47V-01A-11R-A23W-07 | — | — | 0.914 |
| 5 | SRR6013548 | — | cohortA1 | 0.912 |
| 6 | sclcMAD11162_S44.txt | — | cohortA1 | 0.911 |
| 7 | BS_NH7K4CD9 | EPN | Posterior Fossa EPN | 0.911 |
| 8 | MNG96 | — | — | 0.909 |
| 9 | TCGA-49-AAR4-01A-12R-A41B-07 | — | cohortA1 | 0.907 |
| 10 | SRR1475803 | GTEX | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |